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Supplementary information
Materials and Methods
Auoxo3 loading into the AFt nanocage
5 Horse spleen ferritin (Ft) was purchased from Sigma and used 
without further purification. Auoxo3 was prepared as previously 
described [1]; it is a ca. 1:1 mixture of the cis and trans isomers. 
Stock solution of Ft (code F4503) was the same used to prepare 
the CDDP-encapsulated AFt [2]. The solution was stored at 4 °C 
10 in 0.15 mM sodium chloride and contains iron in a protein 
subunit to metal ratio of 1:26.5, according to inductively coupled 
plasma mass spectrometry (ICP-MS) measurements. 
The Auoxo3-encapsulated AFt was prepared following the 
procedure previously used to obtain CDDP-encapsulated AFt 
15 complex [2]. The loading was achieved by breaking down and 
then reassembling the Ft nanocage. Briefly, Ft (20 mg x mL-1) 
was incubated at pH 13 in the presence of Auoxo3 (protein 
subunit to metal drug molar ratio 1:75); then this mixture was 
gently slowed down at neutral pH. In particular, the protein 
20 sample was slowly raised to pH 13 in the presence of Auoxo3 
with 1 M NaOH (final concentration 0.1 M NaOH) and after 
30 min, the pH of the resulting solution was adjusted to 7.4 using 
1.0 M sodium phosphate buffer. After this process, the sample 
was extensively centrifuged at 5 000 rpm to remove the abundant 
25 precipitates (10 min); then it was recovered and ultra-filtrated (10 
kDa cutoff) against 10 mM sodium phosphate buffer, pH 7.4. 
ICP-MS measurements indicate that Auoxo3-encapsulated Ft 
contained Au in a 1:8.8 Ft subunit:Auoxo3 ratio, i.e. 1:17.6 Ft 
subunit to metal ratio, and an undetectable amount of iron, thus 
30 the protein is in the Apo form (AFt). 
The encapsulation of Auoxo3 in the AFt core was also assessed 
spectrophotometrically by comparing the UV-Vis spectra of 
Auoxo3-encapsulated AFt with those of the protein used as 
control (see below). 
35 Control experiments indicate that Auoxo3 is stable at pH 13. In 
particular, to control the stability of Auoxo3 at pH 13, 53 mg 
(0.05 mmol) of the compound were treated with ca. 20 mL of 
NaOH 0.1 M (pH = 13) and the resulting suspension stirred for 
45 min at room temperature, during which the color of the 
40 suspension turned from yellow to dark grey. Then the solid 
product was filtered under vacuum and extracted with MeCN and 
filtered through Celite to remove some metallic gold. The filtered 
yellow solution was concentrated to a small volume and diethyl 
ether added to give 34.6 mg (65 %) of the starting complex, as 
45 shown by its 1H NMR spectrum in CD3CN (Figure S5).
Crystallization and X-ray diffraction data collection
Crystals of Auoxo3-encapsulated AFt with diamond-like 
morphology, suitable for X-ray diffraction data collection, were 
50 grown by hanging-drop vapor diffusion technique at 293 K 
mixing the protein (5-10 mg x mL-1) with equal volumes of a 
reservoir solution consisting of 0.6-0.8 M (NH4)2SO4, 0.1 M Tris 
pH 7.4-7.7, 50-60 mM CdSO4. 
X-ray diffraction data for Auoxo3-encapsulated AFt were 
55 collected from single crystals using a Saturn944 CCD detector 
equipped with CuKα X-ray radiation from a Rigaku Micromax 
007 HF generator at the CNR Institute of Biostructures and 
Bioimages, Naples, Italy. Crystals were cryoprotected by adding 
glycerol to the mother liquor (final concentration= 25%) and 
60 flash cooled at 100 K. Data sets were indexed, integrated, 
reduced and scaled using HKL2000 [3] and the indications 
reported by Karplus and Diederichs [4]. Data collection statistics 
are reported in Table S2. 
65 Structure resolution and refinement 
The structure of Auoxo3-encapsulated AFt was solved by 
molecular replacement method, using the protein file 5ERK [2], 
without water molecules and other ligands, as a search probe and 
the program Phaser [5]. The crystals of this protein were obtained 
70 under the same experimental conditions, using a protein sample 
that was subjected to the same treatment used to encapsulate 
CDDP [2]. The structure was refined following the protocol used 
to refine the structure of CDDP-encapsulated AFt with 
Refmac5.7 [6]. Model building and map inspections were 
75 performed using Coot [7]. Gold ions were located if strong 
signals were observed in the 2Fo-Fc, Fo-Fc and anomalous 
electron density maps of Auoxo3-encapsulated AFt, but absent in 
the same positions in the corresponding maps of the starting 
model, which is a good control [2]. In the assignment of the metal 
80 centre, the nature and the arrangement (geometry) of the 
surrounding atoms were also considered. 
To add confidence to out assignments, a detailed comparison of 
the binding specificity of gold ions versus cadmium ions to amino 
acids has been performed and the expected metal to ligand atom 
85 bond distances have been evaluated considering the standard 
uncertainties calculated using the ‘Calc dpi’ webserver [8].  
According to statistical analysis carried out using a non-
redundant dataset of 195 cadmium-bound proteins, Cd ions have 
a strong preference for glutamic acid and aspartic acid, although 
90 they can also bind the basic amino acid histidine and the polar 
amino acid cysteine [9]. The distance between Cd ions and atoms 
belonging to these side chains are on average = 2.3 Å for 
nitrogen, 2.4 Å for oxygen and 2.5 Å for sulfur [9]. 
Considering 1) the low affinity for Cd for sulfurs [9], 2) the high 
95 affinity of gold for Cys (formation of stable coordinative bonds to 
soft ligands) [10], 3) the distances between the electron density 
peaks and sulfur atoms of Cys residues in our structure (1.9 and 
2.2 Å), it can be concluded that it is highly probable that Au 
atoms are bound to Cys48 and Cys126 side chains. 
100 Regarding the binding to ND1 atom of His49 and His132 and 
NE2 atom His147, the distances between the electron density 
peaks and N atoms of His side chains are in the range 2.1-2.6 and 
thus these positions could be in principle occupied by Cd ions. 
CREATED USING THE RSC COMMUNICATION TEMPLATE (VER. 3.1) - SEE WWW.RSC.ORG/ELECTRONICFILES FOR DETAILS
ARTICLE TYPE www.rsc.org/xxxxxx  |  XXXXXXXX
This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  3
However, binding of Cd ions to ND1 atom of His49 and His132 
and to NE2 atom of His147 is not observed in the crystals of the 
native protein used as control and in those of the cisplatin-
encapsulated adduct grown under the same experimental 
5 conditions [2] and even in all the structures of horse spleen 
ferritin deposited in the protein data bank (see Table S2 in the SI 
of ref [2]). A comparison of the Cd binding site location in 
Auoxo3-encapsulated AFt and in previously determined 
structures of CCDP-encapsulated AFt and of the control, grown 
10 under the same experimental conditions used for Auoxo3-
encapsulated AFt, are reported in Table S3. As an additional 
comment, it should be also recalled that gold ions were found 
close to the side chains of Cys48, His49, His114 and Cys126 also 
in the X-ray structure of horse liver apo-Ft with AuCl4- by other 
15 authors (pdb code 3H7G) [11]. 
A detailed comparison of the native ferritin Cd binding sites and 
their own anomalous difference map peak heights with the 
binding sites in the Auoxo3-encapsulated AFt has been also 
performed.  This comparison is reported in Table S4. Considering 
20 that gold f " at =1.5418 Å is about 1.5 times larger than that of 
Cd and also considering the analysis performed and discussed in 
previous paragraphs, we conclude that peaks that we have 
interpreted as due to Au ions are correctly assigned. We cannot 
exclude that other peaks, which we have assigned to Cd ions (for 
25 example Cd9) could be due to Au. However, since there are 
known structures of AFt where these positions are occupied by 
Cd ions (see for example PDB codes 2GYD, 2V2I, 2V2J, 2V2N, 
2V2O, 2W0O, 1XZ3) and we cannot confirm Au/Cd 
replacement, we prefer to put Cd ions in these sites, according to 
30 recent guidelines suggested by Helliwell and co-workers: “If you 
are not sure, do not make an assignment”.
The presence of Au ions bound to the protein unambiguously 
demonstrate that the Auoxo3 compound is broken down. 
However, to exclude the possibility that the full, starting gold 
35 compound could be bound to the protein, the distance between 
anomalous peaks of our structure was compared to the Au-Au 
distance observed in the X-ray structure of Auoxo3. Which is 
close to 3.0 Å [12]. There is only one site where there are two 
anomalous peaks at a distance comparable with those found in 
40 Auoxo3 (3.1 Å, Table S5): This site corresponds to the one where 
gold atoms are bound to Cys48 side chain. Here, there is not 
enough space to accommodate the whole Auoxo3 compound. In 
this respect, it should be also recalled that degradation of Auoxo3 
and of other members of Auoxos series upon protein binding has 
45 been already observed in previous studies [13-16] and that it is 
rather well accepted the idea that Auoxos are sensible toward 
even very mildly reducing conditions, suggesting that they very 
likely undergo reduction to gold(I) or to colloidal gold upon 
protein binding.
50 Refinement statistics are reported in Table S2. Structure 
validations were carried out using Whatcheck [17]. In the final 
Fo-Fc difference electron density map, there are 17 peaks whose 
chemical interpretation is not possible and is commented in Table 
S6. Coordinates and structure factors of the Auoxo3-encapsulated 
55 AFt were deposited in the Protein Data Bank with PDB code 
5IX6. 
Spectrophotometric measurements
Auoxo3-encapsulated ferritin samples were analyzed by UV-vis 
absorption spectroscopy with a Cary UV−vis spectrophotometer 
60 with temperature controller using a quartz cuvette with 1 cm path 
length in the range of 240−700 nm. UV-Vis spectra were 
recorded in 10 mM sodium phosphate pH 7.4 and using the 
protein at concentration 0.25 mg x mL-1. Data, reported in Figure 
S3, indicate that gold nanoparticles are probably formed within 
65 our sample over time, although in a small amount. Spectra also 
indicate that Auoxo3-encapsulated ferritin samples are stable for 
months.
 
Circular dichroism (CD) spectra were collected on a Jasco 
70 spectropolarimeter in the wavelength range 190−250 nm (far-
UV) using protein concentration 0.1 mg x mL-1 in 10 mM sodium 
phosphate pH 7.4 (Figure S1). 
Hydrodynamic radius (Z-average) of Auoxo3-encapsulated AFt 
was determined at 25 °C using a Zetasizer Nano ZSP (Malvern 
75 Instruments, Malvern, U.K). The average size (Z-average) of 
fresh solutions of Auoxo3-encapsulated AFt is 13.8 nm, in good 
agreement with what is found by other authors for cisplatin-
encapsulated AFt [18]. Results are the average of three 
measurements. Aged samples of the Auoxo3-encapsulated AFt 
80 are not monodisperse, since they contain the protein and probably 
variable amounts of gold nanoparticles that can be formed inside 
the cage (for example a DLS peak centered at 6 nm is sometimes 
observed).
85 Inductively coupled plasma mass spectrometry
Protein samples were suspended in 600µl HNO3 60% and 200µl 
HCl 37% overnight at 90 °C. Aliquots of acid solution from each 
sample were directly analyzed by ICP-MS. The solution was then 
transferred into polystyrene liners, and diluted 1:10  v/v with 5% 
90 HNO3 and finally analyzed with an Agilent 7700 ICP-MS from 
Agilent Technologies, equipped with a frequency-matching RF 
generator and 3rd generation  Octopole Reaction System (ORS3), 
operating with helium gas in ORF. The following parameters 
were used: radiofrequency power 1550 W, plasma gas flow 14 
95 L/min; carrier gas flow 0.99 L/min; He gas flow 4.3 mL/min. 
103Rh was used as an internal standard (50 μg x L-1 final 
concentration). Au calibration standards were prepared dissolving 
Auoxo3 in 5% HNO3 at 4 different concentrations (1, 10, 50, and 
100 μg x L-1). Au concentration was measured. All the analyses 
100 were performed as triplicates.
Cytotoxicity, Au uptake and Western blotting analysis
Human breast cancer cells (MCF-7), cervical cancer cells (HeLa), 
105 hepatic carcinoma cells (HepG2), human keratinocyte cells 
(HaCaT), rat cardiomyoblasts cells (H9c2) were from ATCC and 
were cultured in Dulbecco’s modified Eagle’s medium (Sigma-
Aldrich), supplemented with 10% fetal bovine serum (HyClone, 
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Logan, UT, USA), 2 mM L-glutamine and antibiotics. The 
growth medium of H9c2 cells was implemented with 2 mM L-
glutamine and 2 mM sodium pyruvate. Human renal cortical 
epithelial cells HRCE (Innoprot, Biscay, Spain) were cultured in 
5 basal medium, supplemented with 2% fetal bovine serum, 
epithelial cell growth supplement, and antibiotics, all from 
Innoprot. All cells were grown in a 5% CO2 humidified 
atmosphere at 37 °C.
Cells were seeded in 96-well plates at a density of 2.5 × 103/well. 
10 24 h after seeding, cells were incubated with increasing amount 
of the protein under test (from 12 to 77 μg x mL-1) for 72 h. At 
the end of incubation, cell viability was assessed by the MTT 
assay as previously described [19]. Cell survival was expressed as 
percentage of viable cells in the presence of the analysed protein, 
15 with respect to control cells. Control cells are represented by cells 
grown in the absence of protein and by cells supplemented with 
identical volumes of protein buffer (10 mM sodium phosphate 
buffer, pH 7.4). 
To investigate Au uptake and to perform western blot analysis, 
20 the Auoxo3-encapsulated AFt amount able to induce 50% 
mortality (IC50) was used. MCF-7 cells were incubated for 24, 48 
and 72 h with the Auoxo3-encapsulated AFt and uptake was 
evaluated as previously reported [20]. Results are reported in 
Table S7.
25 To perform western blot analyses, cell lysates were analyzed as 
previously reported [20]. Results of these analyses are reported in 
Figure S4. Positive control was obtained by incubating cells in 
the presence of 50 µg/mL puromycin for 24 h.
30
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Table S1. Interactions between Au atoms and protein residues or 
solvent atoms in the structurte of Auoxo3-erncapsulated AFt.
    Binding site Distance (Å)    Angle (°)
Cys48 and His49
5 Au2-SG Cys48 1.9
Au6- centroid His49 3.2
SG Cys48-Au6-centroid His49       152.5
Au6-SG Cys48 2.3
Au2-Au6 3.1
10       His49
Au3-ND1 His49 2.1
Cys126 and His114
Au1-SG Cys126 2.2
Au1-ND1 His114 2.2
15 SG Cys126-Au1-ND1 His114       178.6
Au4-SG Cys126 2.2
Au4-O Wat 2.5
SG Cys126-Au4-O Wat         173.1
Au1-Au4 3.7
20       His132
Au7-ND1 His132 2.5
                      His147
Au5-NE2 His147 2.6
Unrestrained selected bond distances and angles are in Å and °, 
25 respectively. Standard uncertainties on the coordinates 0.1 Å. 
Errors on distances<0.2 Å 
Table S2. Data Collection and refinement statistics
Data reduction
30 PDB code 5IX6
Space group                 F432
Unit cell parameters
a=b=c (Å) 180.645
Molecules per asymmetric unit 1
35 Observed reflections 151428
Unique reflections 22027
Resolution (Å) 104.30-1.85 (1.88-1.85)
Completeness (%) 99.5 (95.0) 
Anomalous completeness (%) 99.2 (88.1)
40 Rpim in top intensity bin 0.032 
Rpim 0.102 (0.659)
 I/σ(I) 9.2 (0.8)
Multiplicity 6.9 (3.4)
C1/2 last shell 0.284
45 CC* 0.666
Refinement
Resolution (Å) 104.30-1.85
number of reflections in working set 20893
50 number of reflections in test set 1128
R-factor/Rfree/Rall (%) 18.0/18.2/22.6
Non-H atoms used in the refinement 1785
Mean B-value (Å2) 19.7
Au atom occupancy 0.40, 0.30, 0.35, 0.45, 
55 0.25,   0.45 and 0.20 
Au atom B-factor (Å2) 20.0, 34.8, 29.5, 20.6, 
38.9,   38.7 and 50.5
Estimated overall coordinate errors
Rmsd bonds (Å) 0.019
60 Rmsd angles (°) 1.77
Ramachandran values (%) from Coot
Preferred region 96.32
Allowed 2.94
Disallowed 0.74 (1 residue:Ser157)
65
Parentheses indicate information for highest resolution shell.
70
75
80
85
90
95
100
105
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Table S3. Interactions of Cd2+ ions in Auoxo3-encapsulated AFt, CCDP-encapsulated AFt and in 
the control
Auoxo3-
encapsulated 
AFt
Auoxo3-
encapsulated AFt
CDDP-
encapsulated Aft 
and Control
CDDP-
encapsulated AFt Control
CDDP-
encapsulated AFt 
(crystal 2)
Atom
Interactions at 
distance
< 3.00 Å
Atom
Interactions at 
distance
< 3.00 Å
Interactions at 
distance
< 3.00 Å
Interactions at 
distance 
< 3.00 Å
CD1 Occupancy 0.40
B-factor 40.5 Å2
OE1 Glu11 (2.6 Å)
OE2 Glu11 (2.8 Å)
WAT 129 (2.2 Å)
WAT 384 (2.7 Å)
WAT 399 (2.8 Å)
WAT 447 (2.2 Å)
CD1
Occupancy 0.40
B-factor 22.9 Å2
OE1 Glu11 (2.3 Å)
OE2 Glu11 (2.6 Å)
WAT 129 (2.2 Å)
WAT 183 (2.3 Å)
Cl 3 (2.60 Å)
Occupancy 0.40
B-factor 42.4 Å2
OE1 Glu11 (2.7 Å)
OE2 Glu11 (2.3 Å)
WAT 129 (2.8 Å)
WAT 319 (2.6 Å)
Cl 3 (2.5 Å)
Occupancy 0.40
B-factor 41.4 Å2
OE1 Glu11 (2.7 Å)
OE2 Glu11 (2.5 Å)
WAT 129 (2.0 Å)
WAT 183 (2.6 Å)
Cl 4 (2.6 Å)
CD2
Occupancy 0.45
B-factor 58.66 Å2
OE1 Glu56 (2.5 Å)
CD2
Occupancy 0.40
B-factor 43.7 Å2
OE1 Glu53 (2.9 Å)
OE2 Glu53 (2.4 Å)
OE1 Glu56 (2.5 Å)
WAT 237 (2.5 Å)
Occupancy 0.30
B-factor 51.9 Å2
OE1 Glu53 (2.5 Å)
OE2 Glu53 (2.6 Å)
OE1 Glu56 (2.5 Å)
WAT 315 (2.3 Å)
Occupancy 0.40
B-factor 51.8 Å2
OE1 Glu53 (2.9 Å)
OE2 Glu53 (2.9 Å)
OE1 Glu56 (2.4 Å)
WAT 302 (2.9 Å)
CD8
Occupancy 0.40
B-factor 41.9 Å2
OE1 Glu60 (2.8 Å)
OE2 Glu60 (2.4 Å)
OE1 Glu56 (2.7 Å)
OE2 Glu57 (2.7 Å)
WAT 471 (2.5 Å)
CD3
Occupancy 0.30 
B-factor 44.0 Å2
OE2 Glu56 (2.4 Å)
OE1 Glu60 (2.8 Å)
OE2 Glu60 (2.2 Å)
Occupancy 0.20 
B-factor 35.80 Å2
OE1 Glu60 (2.4 Å)
WAT 191 (2.2 Å) 
Occupancy 0.30 
B-factor 69.1 Å2
OE1 Glu60 (2.5 Å)
WAT 292 (2.8 Å)
Occupancy 0.30 
B-factor 56.4 Å2
OE2 Glu56 (2.9 Å)
OE1 Glu60 (2.8 Å)
OE2 Glu60 (2.7 Å)
Occupancy 0.20 
B-factor 60.5 Å2
OE1 Glu60 (2.4 Å)
WAT 191 (2.4 Å)
Cl 6 (2.7 Å)
CD3
Occupancy 0.50
B-factor  Å2
OD1 Asp80 (2.4 Å)
OD2 Asp80 (2.2 Å)
OD1 Asp80* (2.4 
Å)
OD2 Asp80* (2.2 
Å)
WAT 386 (2.4 Å)
WAT 386* (2.4 Å) CD4
at the binary axis
Occupancy 0.40
B-factor 10.5 Å2
OD1 Asp80 (2.3 Å)
OD2 Asp80 (2.5 Å)
OD1 Asp80* (2.3 
Å)
OD2 Asp80* (2.5 
Å)
Cl 1 (2.4Å)
Cl 1* (2.5 Å)
Occupancy 0.10
B-factor 19.5 Å2
OD1 Asp80 (2.1 Å)
OD2 Asp80 (1.9 Å)
OD1 Asp80* (2.2 
Å)
OD2 Asp80* (2.1 
Å)
Cl 1 (2.9 Å)
Occupancy 0.50
B-factor 15.7 Å2
OD1 Asp80 (2.4 Å)
OD2 Asp80 (2.1 Å)
OD1 Asp80* (2.5 
Å)
OD2 Asp80* (2.3 
Å)
Cl 2 (2.6 Å)
Cl 2* (2.3 Å)
Occupancy 0.50
B-factor 16.4 Å2
OD1 Asp80 (2.5 Å)
OD2 Asp80 (2.2 Å)
OD1 Asp80* (2.5 
Å) 
OD2 Asp80* (2.4 
Å)
Cl 1 (2.5 Å)
Cl 1* (2.7 Å)
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Cl 1* (3.0 Å)
- -
CD5
Occupancy 0.30 
B-factor 44.4 Å2
OE2 Glu88 (2.3 Å)
WAT 81 (2.0 Å)
WAT 181 (2.2 Å)
WAT 187* (2.6 Å)
Occupancy 0.20 
B-factor 61.0 Å2
OE2 Glu 88 (2.3 Å)
WAT 313 (2.5 Å)
WAT187* (2.7 Å)
-
- -
CD6
Occupancy 0.40
B-factor 45.3 Å2
OG Ser131 (2.7 Å)
OD1 Asp127 (3.0 
Å)
WAT 196 (2.5 Å)
WAT 197 (2.5 Å)
WAT 230 (2.0 Å)
Occupancy 0.40
B-factor 69.3 Å2
OD1 Asp127 (2.9 
Å)
WAT 245 (2.5 Å)
WAT 311 (2.2 Å)
Occupancy 0.40
B-factor 62.5 Å2
OD1 Asp127 (2.4 
Å)
WAT 196 (2.8 Å) 
CD4 Occupancy 0.50
B-factor 43.6 Å2
NE2 His132 (2.2 
Å)
WAT335 (2.1 Å) CD7
Occupancy 0.50
B-factor 42.1 Å2
NE2 His132 (2.5 
Å)
OD2 Asp135* (2.9 
Å)
WAT 196 (2.4 Å)
WAT 197 (2.5 Å)
WAT 275 (1.7 Å)
Occupancy 0.40
B-factor 39.9 Å2
NE2 His132 (2.7 
Å)
WAT 245 (2.2 Å)
WAT 246 (2.2 Å)
WAT 294 (2.1 Å)
WAT 295 (2.4 Å)
Occupancy 0.50
B-factor 60.2 Å2
NE2 His132 (2.7 
Å)
WAT196 (2.3 Å)
WAT197 (2.5 Å)
WAT275 (2.4 Å)
CD5 Occupancy 0.30
B-factor 28.2 Å2
OE1 Glu130 (2.5 
Å)
OE2 Glu130 (2.5 
Å)
OE1 Glu130* (2.5 
Å)
OE2 Glu130* (2.5 
Å)
OE1 Glu130* (2.5 
Å)
OE2 Glu130* (2.5 
Å)
CD8 
at the ternary axis
Occupancy 0.20
B-factor 42.7 Å2
OE1 Glu130 (2.4 
Å)
OE1 Glu130* (2.4 
Å)
OE1 Glu130* (2.4 
Å)
Cl 2 (1.9 Å)
Cl 2* (1.9 Å)
Cl 2* (1.9 Å)
Occupancy 0.20
B-factor 46.5 Å2
OE1 Glu130 (2.5 
Å)
OE1 Glu130* (2.5 
Å)
OE1 Glu130* (2.4 
Å)
Cl 2 (2.3 Å)
Cl 2* (2.3 Å)
Cl 2* (2.3 Å)
Occupancy 0.30
B-factor 61.3 Å2
OE1 Glu130 (2.3 
Å)
OE1 Glu130* (2.3 
Å)
OE1 Glu130* (2.3 
Å)
Cl 5 (2.9 Å)
Cl 5* (2.9 Å)
Cl 5* (2.9 Å)
- - CD9
Occupancy 0.40
B-factor 56.5 Å2
NE2 His114 (2.7 
Å)
WAT 265* (2.9 Å)
Occupancy 0.20
B-factor 59.1 Å2
WAT 252* (2.5 Å)
Cl 1* (2.9 Å)
Occupancy 0.40
B-factor 72.6 Å2
NE2 His114 (2.8 
Å)
WAT 265* (2.8 Å)
Cl 5* (2.7 Å)
- -
CD10
Occupancy 0.30 
B-factor 42.1 Å2
OE1 Glu63/A (2.7 
Å)
OE2 Glu63/A (2.3 
Å)
OE2 Glu63/B (2.3 
Å)
WAT 85 (1.7 Å)
WAT 247 (2.5 Å)
Occupancy 0.20 
B-factor 51.5 Å2
OE1 Glu63 (2.6 Å)
Occupancy 0.30 
B-factor 62.5 Å2
OE1 Glu63 (2.9 Å)
WAT 85 (2.4 Å)
WAT 219 (2.8 Å)
- - CD11 Occupancy 0.30 B-factor 30.9 Å2
Occupancy 0.30
B-factor 33.6 Å2
Occupancy 0.30
B-factor 25.2 Å2
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SG Cys48 (2.0 Å)
WAT 231 (2.0 Å)
SG Cys48 (2.1 Å)
WAT 310 (2.0 Å)
SG Cys48 (2.0 Å)
WAT 231 (1.8 Å)
- -
CD12
Occupancy 0.40 
B-factor 56.8 Å2
OE2 Glu45/B (2.4 
Å)
WAT 255 (2.2 Å)
Cl 5 (2.7 Å)
Occupancy 0.30 
B-factor 73.9 Å2
OE1 Glu45 (2.5 Å)
WAT 235 (2.2 Å)
Occupancy 0.40 
B-factor 66.7 Å2
OE2 Glu45 (2.6 Å)
WAT 282 (2.9 Å)
CD6 Occupancy 0.35
B-factor  65.1 Å2
OE1 Glu45/A (2.9 
Å)
WAT 364 (2.9 Å)
WAT 387 (2.0 Å)
CD13
Occupancy 0.20
B-factor 44.1 Å2
OE1 Glu45/A (2.2 
Å)
NE2 His49 (2.3 Å)
Occupancy 0.20
B-factor 44.1 Å2
OE2 Glu45/A (2.5 
Å)
NE2 His49 (2.7 Å)
WAT 236 (2.9 Å)
Occupancy 0.20
B-factor 57.4 Å2
OE1 Glu45/A (2.2 
Å)
NE2 His49 (2.5 Å)
CD7 Occupancy 0.20
B-factor  37.4 Å2
WAT 332 (2.3 Å)
WAT 333 (2.4 Å)
WAT 332 *(2.3 Å)
WAT 333 *(2.4 Å)
WAT 332 *(2.3 Å)
WAT 333 *(2.4 Å)
- - - -
CD9 Occupancy 0.15
B-factor  42.1 Å2
OE1 Glu53 (1.9 Å)
- - - -
* Symmetry related residue
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Table S4. Anomalous map peak intensities in the structure reported in this work compared to those 
obtained using crystals of AFt, CDDP-encaspulated AFt and an additional internal control collected 
using X-ray from a CuKa generator.
Atom name 
in the 
Auoxo3-
encapsulated 
AFt
Auoxo3-
encapsulated 
AFt
Corresponding 
atoms
in  the 
structures of 
CDDP-
encapsulated 
AFt and in the 
control
CDDP-
encapsulated 
Aft
Crystal 1
CDDP-
encapsulated 
Aft
Crystal 2
Control Notes
Resolution 
1.85 Å
Resolution 
2.06 Å
Resolution 
1.45 Å
Resolution 
1.82 Å
λ used for 
data 
collection
0.15418 nm
λ used for 
data 
collection
0.15418 nm
λ used for 
data 
collection
0.1065 nm
λ used for 
data 
collection
0.1065 nm
Notes
Atom e/Å3 Atom e/Å3 e/Å3 e/Å3
CD1 0.22 CD1 0.24 0.28 0.14
CD2 0.21 CD2 0.16 0.12 0.10
CD8 0.20 CD3 0.31 0.10/0.08 0.12
CD3 1.19 CD4 0.92 1.16 0.53
- - CD5 - 0.09 0.09
- - CD6 0.35 0.12 0.09
CD4 0.25 CD7 0.28 0.17 0.09
CD5 0.58 CD8 0.41 0.15 0.11
- - CD9 0.25 0.15 0.10
- - CD10 0.30 0.07 0.09
- - CD11 0.25 0.06 0.10
- - CD12 0.30 0.09 0.10
CD6 0.22 CD13 0.21 0.09 0.16
CD7 0.36 - - - - Not bound 
to protein 
residues, 
but to six 
water 
molecule 
(octahedral 
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geometry)
CD9 0.19 - - - - Close to 
Glu53, as in 
other 
structures 
of AFt
Au1 0.76 - - - - Close to 
Cys126
Au2 0.37 - - - - Close to 
Cys48
Au3 0.52 - - - - Close to 
His49
Au4 1.00 - - - - Close to 
Cys126
Au5 3.14 - - - - Close to 
His147
Au6 0.50 - - - - Close to 
Cys48
Au7 0.16 CPT 0.21 0.24 - Close to 
His132
- - -
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Table S5. Distances between main anomalous peaks in the structure of Auoxo3-encapsulated AFt
distance Assignment
3.1 Å Au2-Au6
3.7 Å Au1-Au4
3.9 Å Au3-Au6
5.0 Å Cd5-Cd7
5.3 Å Cd2-Cd8
5.3 Å Au2-Au3
6.2 Å Au7-Cd4
6.5 Å Au3-Cd2
6.5 Å Au3-Cd9
6.6 Å Cd2-Cd9
7.6 Å Au1-Cd5
7.7 Å Au4-Cd5
8.4 Å Au5-Cd9
9.1 Å Au6-Cd9
9.5 Å Au6-Cd6
9.8 Å Cd4-Cd7
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Table S6. Uninterpreted Fo-Fc electron density map peaks in the structure of Auoxo3-encapsulated 
AFt at level > 5  
Peak 
number
e/Å3 Rmsd 
()
Note
1 1.08 9.15 Too close  to Cd8 (1.9 Å)
2 0.96 8.06 Too close to CD atom of Arg153 (2.2 Å)
3 0.95 7.99 Too close to CE and NE atoms of His114 
(0.7 and 0.8 Å, respectively)
4 0.90 7.63 Too close to CD2 atom of His114 (1.9 Å) 
5 0.76 6.43 Too close to OD2 atom of Asp127 and to 
Wat311 (1.8 and 1.4 Å, respectively) 
6 0.73 6.17 Too close to OE2 atom of Glu56 and to Cd8 
(1.8 and 1.4 Å, respectively) 
7 0.71 6.02 On symmetry  axis
8 0.67 5.63 Too close to Wat248 (1.5 Å)
9 0.66 5.54 Too close to Wat334 and to OE2 atom of 
Glu130 (1.9 and 2.3 Å, respectively)
11 0.64 5.37 Too close to Wat382 (1.7 Å)
12 0.63 5.32 Too close to Wat386 (1.3 Å)
13 0.63 5.29 Too close to CE atom of Met96 (< 0.3 Å)
14 0.63 5.28 Too close to Au4 and to Wat 373
(1.5 and 1.8 Å, respectively)
15 0.61 5.14 Too close to CD and OE atoms of Glu63
(1.8 and 1.7 Å, respectively)
16 0.61 5.13 Too close to Wat 334 ( 1.7 Å)
17 0.60 5.05 Too close to OE1 atom of Glu57 and to 
Wat358 ( 2.1 and 1.3 Å, respectively)
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Table S7. Cellular uptake of Au associated with Auoxo3-encaspulated AFt by MCF-7 cells during 
24, 48 and 72 h normalized to 1x 106 cells.*
  24h 48h 72h
Sample    
Au (%) Au (%) Au (%)
Total amount 100 100 100
Cell conditioned medium 87.5 71.4 68.4 
Cell washing 3.1 1.2 3.6
Cell lysate 9.0 11.9 21.6
*Average of two different measurements. Errors about 10%.
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Figure S1. Far-UV CD spectra of Auoxo3-encapsulated AFt (black) compared to the control (red).
Figure S2. Comparison between Au binding sites observed in the structure of horse liver ferritin with AuCl4- (A) and in Auoxo3-
encapsulated AFt (B). 2Fo-Fc electron density maps are contoured at 1 (cyan) and 4  (orange). The structure of horse liver ferritin 
with AuCl4- is coloured in green; the structure of Auoxo3-encapulstaed Aft is coloured in cyan
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Figure S3. UV-vis absorption spectra of 0.25 mg x mL-1Auoxo3-encapsulated AFt (black) compared to the control (red). The 
absorption differences between 250 and 280 nm and the appearance of a peak at 548 nm in aged samples confirm that Auoxo3 was 
successfully encapsulated in the AFt nanocage and suggest that a small amount gold nanoparticles could be formed in Auoxo3-
encapsulated AFt sample.
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Figure S4. Detection of apoptosis in Auoxo3-encapsulated AFt-treated MCF-7 cells. MCF-7 cells were pre-incubated with 0.4 
μg/mL Auoxo3-encapsulated AFt for 24, 48 and 72 h. Western blot was performed using anti-Caspase 3, which recognizes both pro-
Caspase 3 and the activated form. GAPDH was used as loading control. A positive control was obtained by incubating cells in the 
presence of 50 µg/mL puromycin for 24 h.
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Figure S5. 1H NMR (CD3CN, 400 MHz) of Auoxo3 recovered from reaction with NaOH 0.1M
